ArticleProceedings of the National Academy of Sciences of the United States of America2025
Engineering a serum response factor superactivator of smooth muscle gene expression with a condensate-forming domain.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Spatial expression of myocardin protein in normal and disease states.American journal of physiology. Cell physiology · 2026Article
- Enhancer Dynamics for Gene Regulation in the Cardiovascular System.Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Temporal Proteomic Remodeling of Cerebral Arteries in Male Hypertensive Rats.Hypertension (Dallas, Tex. : 1979) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Differentiation of smooth muscle cells (SMCs) is driven by the activation of a set of genes controlled by serum response factor (SRF), a ubiquitous transcription factor with limited intrinsic transcriptional activity. Myocardin (MYOCD) is a strong transcriptional coactivator that orchestrates smooth muscle differentiation through its association with SRF. MYOCD forms nuclear condensates via its intrinsically disordered transcription activation domain (TAD), whereas SRF is diffusely distributed in the nucleus. MYOCD recruits SRF into these condensates, thereby activating the smooth muscle gene program. We engineered a "superactivator" of smooth muscle genes by replacing SRF's weak TAD with that of MYOCD, thereby enabling SRF to form nuclear condensates and reprogram fibroblasts into SMCs. Using protein proximity labeling, quantitative proteomics and superresolution confocal microscopy, we show that condensates formed by the MYOCD TAD aggregate chromatin remodelers, RNA polymerases, and mRNA processing factors to drive smooth muscle gene expression. These findings provide insights into the mechanisms whereby nuclear condensates facilitate tissue-specific gene expression and highlight a strategy for engineering cell fate determinants by coupling condensate-forming domains to heterologous DNA-binding proteins.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.